Øivind Enger

Novel Diagnostics AS provides biomedical research and diagnostics development services. It sells and develops medical and diagnostic products and drives commercialization of research results. The firm also invests in securities; either in form of follow-up investments in companies already has invested in, or as part of other strategic investments. The company was founded on June 10, 2002 and is headquartered in Bergen, Norway.

Sarsia Innovation AS invests in companies located in the northern part of Norway. Selected companies are from various sectors but they all are developing new concepts in their field. The fund is currently closed for new investments.

Sarsia Seed Management AS is a venture capital firm headquartered in Bergen, Norway. The company was founded in 2006.

Blue Limit AS is a holding company that develops, protects, produces, and sells early stage larvae feed for shrimp and mollusks. The firm offers feed for the vulnerable early development phases of fish and shellfish larvae. It is a norwegian aquaculture feed company that launches shrimp larvae feed. The firm is categorized under other research and experimental development on natural sciences and engineering. The company was founded by Anders Aksnes on June 29, 2006 and is headquartered in Bergen, Norway.

ScreenCancer AS offers cancer screening and diagnostic program to the public. It provides a panel of screening tests for several major cancers such as colorectal, bladder, breast, prostate, skin, and lung. The company was founded by Christian Horn and Dagfinn Steinar Ogreid in 2007 and is headquartered in Sola, Norway.

VoluSense AS manufactures medical devices focused on pulmonary health. It offers VoluSense Pediatrics in the neonatal unit for the infants that provides visual and quantitative information on tidal flow, tidal volume, minute volume, and respiration frequency. The company was founded by Kjell Gunnar Øygarden and is headquartered in Bergen, Norway.

Enso AS is a holding company that develops and commercializes products. It provides technology that uses electricity to neutralize unwanted marine organisms in ballast water. The company was founded on October 20, 2006 and is headquartered in Kleppesto, Norway.

Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway.

Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.